

**In the Claims**

**Please substitute the following claims 16 and 18 for the claims 16 and 18 now pending in the above-identified application.**

**Please cancel claims 10-12 and 27 without prejudice to the filing of future continuing applications.**

Claims 1-8 (Cancelled)

9. (Previously Presented) The method of claim 18 wherein the insulin sensitizer is pioglitazone hydrochloride.

Claims 10 – 15 (Cancelled)

16. (Currently Amended) A method for improving or treating acidosis in a mammal in need thereof which comprises administering to said mammal an effective amount of an insulin sensitizer in combination with insulin, wherein the insulin sensitizer is selected from the group consisting of

- 1) pioglitazone or a salt thereof;
- 2) 5-[[6-(2-fluorobenzyloxy)-2-naphthyl]methyl]-2,4-thiazolidinedione;
- 3) CS-011; and
- 4) ~~BM-13-1258.~~ **BM-13-1258;**

**wherein said acidosis is diabetic acidosis or acidosis caused by a biguanide.**

Claim 17 (Cancelled)

18. (Currently Amended) A method for improving or treating acidosis in a mammal in need thereof, which comprises administering to said mammal an effective amount of an insulin sensitizer selected from the group consisting of

- 1) pioglitazone or a salt thereof;
- 2) 5-[[6-(2-fluorobenzyloxy)-2-naphthyl]methyl]-2,4-thiazolidinedione;
- 3) CS-011;

and

4) ~~BM-13-1258~~; BM-13-1258;

wherein said acidosis is diabetic acidosis or acidosis caused by a biguanide.

Claims 19-23 (Cancelled)

24. (Previously Presented) The method of claim 16 wherein the insulin sensitizer is pioglitazone hydrochloride.

Claims 25 -27 (Cancelled)

28. (Previously Presented) The method of claim 18 wherein the insulin sensitizer is selected from the group consisting of

- 1) pioglitazone or a salt thereof, and
- 2) 5-[[6-(2-fluorobenzyloxy)-2-naphthyl]methyl]-2,4- thiazolidinedione.

Claims 29 and 30 (Cancelled)